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1. Introduction
Sepsis is a life-threatening condition 
where the body’s own response to an infec-
tion progressively leads to organ system 
dysfunction, failure and finally death.[1] 
Although the ongoing advancements in 
modern medicine have increased the sur-
vival rates of organ recipients and patients 
with serious illnesses, such as cancer and 
HIV, the occurrence of sepsis has been 
increasing globally, imposing a significant 
challenge.[2] Moreover, the emergence of 
drug-resistant pathogens is contributing 
significantly to the global sepsis threat.[3] 
Current reports indicate that sepsis causes 
mortality reaching up to 50% and affects 
more than 30 million people every year 
worldwide.[2] In the United States alone, 
$24 billion is spent every year for the man-
agement of sepsis, making it the most 
expensive condition to treat.[4] Sepsis pro-
gresses extremely rapidly and is consid-
ered a medical emergency. In fact, sepsis 
progresses so fast that every hour of delay 
in diagnosis and initiating appropriate treatment increases 
the mortality by 7.6%.[5] Therefore, development of point-of-
care devices enabling early and accurate diagnosis of sepsis at 
different clinical settings is an urgent need as they can allow 
timely intervention and lower the mortality rate.[6–8]
However, sepsis diagnosis is not easy, especially in the early 
stages, or when sepsis presents with an atypical clinical picture. 
Early stages of sepsis usually present stealth symptoms with 
significant patient-to-patient heterogeneity, leading to potential 
delays from the onset of sepsis until the most appropriate treat-
ment starts.[9,10] The dysregulated host response to infection, 
which is typically present in sepsis patients, is primarily sup-
ported by an inflammatory process, which is termed SIRS, for 
systemic inflammatory response syndrome. However, it is chal-
lenging to discriminate whether the biological insult leading to 
SIRS is an infectious process or not, an essential criteria for the 
antimicrobial treatment to be worthy and effective.[1] Tradition-
ally, for the microbiological diagnosis of sepsis, blood-culture 
based pathogen investigation is performed, which typically 
takes 4–5 days.[9] The current recommendation is to administer 
broad-spectrum antibiotics as soon as possible, ideally in the 
first hour after sepsis recognition, before a definitive microbio-
logical diagnosis is made based on the pathogen identification 
tests.[11] This approach leads to overuse of antibiotics, which 
worsens the global health challenge of antibiotic resistant 
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bacteria development, because neither all SIRS patients have an 
underlying infectious process, nor all infections are caused by 
bacterial pathogens. In contrast, a new clinical trend in sepsis 
management relies on blood testing to monitor patient’s sys-
temic response for rapid patient stratification. These tests, 
which quantify circulating biomarkers, such as the two most 
universal sepsis-related biomarkers procalcitonin (PCT) and 
C-reactive protein (CRP), help diagnose sepsis timely and 
reduce overprescription of antibiotics. Although these inflam-
matory biomarkers alone cannot be the sole basis for accurate 
sepsis diagnosis, their blood levels provide valuable quantita-
tive information to triage patients based on their anomalous 
response allowing for personalized treatment.[12–18] The current 
gold standard clinical tools to test blood circulating proteins are 
largely based on complex and lengthy immunoassays, such as 
enzyme-linked immunosorbent, immunoturbidimetric (ITA), 
and chemiluminescent (CLIA) immunoassays, which require 
fully equipped clinical laboratories. However, having rapid 
access to the patient’s systemic response, using portable, low-
cost, and easy-to-use devices that can rapidly detect biomarkers 
in a simple manner from small sample volumes can drastically 
improve sepsis care at different clinical settings such as emer-
gency care units, ambulances, and outpatient health centers.
Currently, active ongoing efforts are being undertaken both 
in the biomedical industry and basic research to find new diag-
nostic solutions and develop point-of-care devices to rapidly 
diagnose sepsis on-site in a cost-effective way. For instance, a 
compact device proposed by Samsung (LABGEO IB10) operates 
by detecting PCT with a centrifugal microfluidic disk. Another 
recent technology that is being investigated by Abionic for sepsis 
detection combines nanofluidic channels with centrifugal disk. 
Although nanosized channels can improve the sensitivity they are 
prone to clogging. Moreover, these technologies employ mechani-
cally moving parts that can compromise device robustness over 
time. So far, no portable system has received US Food and Drug 
Administration approval for measuring biomarkers that effec-
tively predict sepsis at the point of care. Research efforts have 
been made to develop devices for sepsis biomarkers detection 
based on optical schemes, including plasmonics and fluorescence. 
Surface plasmon resonance (SPR) and surface-enhanced Raman 
scattering sensors were reported, however they could not achieve 
clinically relevant sensitivity.[19,20] Fluorescent schemes have been 
implemented to detect sepsis markers, however they either rely on 
expensive and bulky optical setups, such as total internal reflec-
tion microscopy,[21] or do not meet clinical sensitivity.[22,23] Prom-
ising recent approaches use microfluidic extraction of cells from 
small amount of patient blood to quantify expression of CD64 
biomarker, however they employ sophisticated design and control 
of microfluidic chip.[24,25] Alternatively, a sensitive system based 
on magnetic beads and fluorescent enzymatic amplification has 
been proposed. The system provides a low limit of detection for 
measuring a sepsis-related biomarker IL-3 but at the expense of 
multiple assay steps and 1 h long detection time.[26]
Here, we report a portable digital nanoparticle-enhanced plas-
monic imager for rapid detection of inflammatory biomarkers 
(DENIS). The unique nanoplasmonic imaging mechanism is 
based on gold nanoparticle (Au-NP) binding to plasmonic gold 
nanohole array (Au-NHA),[27] which enables quantification of 
individual molecule binding on the sensor surface in complex 
media. The bioassay is performed in a single step without signal 
amplification or washing procedures, and the plasmonic detec-
tion is robust against variations in optical properties of samples. 
Importantly, the imager is made of low-cost off-the-shelf optical 
components, and its small size enables deployment and opera-
tion in on-site clinical settings. Moreover, the sensor chips are 
produced in a scalable cost-effective manufacturing and the bio-
assay reagents can be stored stably over weeks. We first show 
the application of DENIS for highly sensitive, quantitative and 
robust detection of PCT and CRP biomarkers. The system 
enables ultrahigh detection sensitivities with limit of detection 
(LOD) down to 21 and 36 pg mL−1 for PCT and CRP, respectively, 
and a wide dynamic range of at least three orders of magnitude. 
We evaluate the performance of DENIS in clinical settings by 
testing the samples from sepsis, noninfectious SIRS (ni-SIRS), 
and healthy subjects provided by Vall d’Hebron Sepsis Bank. We 
benchmarked our results to the clinically validated assays and 
the diagnoses of patients and in agreement, we observed that 
rapid and quantitative detection of PCT and CRP from blood 
serum of the selected 34 subject cohort assisted in discrimina-
tion of healthy and sick groups. Moreover, PCT detection with 
DENIS show performance equivalent to gold standard clinical 
assays in noninfectious SIRS and sepsis patients. Finally, DENIS 
can perform rapid detection by recording video of the plasmonic 
sensor and analyzing the signals in real time. The time-resolved 
results revealed that we can identify samples with high (sepsis) 
and medium (noninfectious SIRS) PCT levels in 5 and 10 min, 
respectively, reducing the test time to under 15 min.
2. Results
2.1. Detection Mechanism
The DENIS detection mechanism is based on a large-area 
Au-NHA device supporting SPR and localized surface plasmon 
modes.[28–31] Au-NHAs exhibit extraordinary optical transmis-
sion (EOT) at its resonance wavelength, controlled by the period 
and geometry of the nanoholes, when illuminated in a collinear 
optical path.[32] This plasmonic resonance is locally distorted 
upon the binding of single Au-NPs (100 nm diameter). These 
distortions result in local suppression in the EOT, which ena-
bles detection of single NP-labeled molecules.[27] Although the 
NPs are subwavelength in size, their plasmonic interaction 
with the Au-NHA allows for high-contrast imaging of surface-
bound NPs in a simple bright field optical reader over large 
field of view directly inside complex samples. The imaged data 
is not affected by the bulk sample background because the reso-
nance transmission through Au-NHAs is strictly dependent on 
the surface localized field with ≈100 nm decay length. More-
over, the contrast generated by a single particle is significantly 
above the noise level induced by the camera and the sample, 
therefore individual molecules binding can be robustly quanti-
fied in a digital way directly in complex media (Figure S1, Sup-
porting Information). In contrast, more conventional affinity 
sensors average the readout over sensor areas, and require a 
certain density of analyte binding to reach a sufficient signal 
to be detected over the system noise, such as background fluc-
tuations or reader noise. The digitized detection of individual 
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particles with DENIS enables highly sensitive quantification 
of low analyte concentrations at the diffusion limit, and statis-
tical assessment of the signal.[27] Importantly, single NPs can 
be distinguished on plasmonic images from NPs aggregates 
and sediment by the size and the shape of the plasmonic image 
spikes.[27]
2.2. Plasmonic Microarray Sensors
We use the detection technique to quantify PCT and CRP bio-
markers from human serum samples. In the presence of the 
biomarker in the sample, antibody-conjugated Au-NPs bind to 
the Au-NHA surface functionalized with complementary anti-
bodies (Figure 1a) and can be detected using a portable reader 
(Figure 1b). Individual Au-NPs bound inside or close to the 
nanoholes (Figure 1c) create strong local intensity contrast 
(Figure 1d), which corresponds to digital detection of single 
analyte molecules.
To enable microarray based multiplexed biosensing, capture 
antibodies are bioprinted on the sensor surface using a high-
throughput, noncontact, low-volume liquid dispenser as shown 
in Figure 1e. The Au-NHA sensors are manufactured using 
a low-cost wafer-scale deep UV lithography (DUVL) and ion 
beam etching (Figure 1f). The nanofabrication process enables 
production of over 50 highly uniformly nanostructured chips 
(1 cm × 1 cm) per 4 in. wafer and eight wafers per batch with 
negligible variation in optical properties.[33] This robustness 
in the manufacturing of nanostructured sensors is critical to 
enable the transfer of the technology to a clinical diagnostic 
tool. We postpatterned the fabricated chips with an array of 
quick response (QR) codes (Figure 1g; Figure S2, Supporting 
Information). In addition to tagging individual chips and 
microarray locations on the chips, QR codes encode the infor-
mation about the fabrication batch parameters and the wafer 
enabling a registry record of the manufactured sensors.
2.3. Portable Optical Reader
The nanoplasmonic imager is made of off-the-shelf optical 
components and comprises a narrowband light emitting diode 
(LED) source, spectrally matching the EOT wavelength of Au-
NHAs, a custom-built aluminum holder for the nanoplasmonic 
chip, an objective, and a CMOS camera. The collimated LED 
light is transmitted through the sample chamber and modu-
lated by the Au-NHA sensor. The sensor images are acquired by 
a 50× objective and CMOS sensor with 4104 × 3006 pixels and 
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Figure 1. Portable digital nanoparticle-enhanced plasmonic imager for biomarkers detection. a) PCT and CRP, which are blood-circulating protein 
biomarkers secreted by the host body in response to systemic inflammation, are detected using DENIS. A single-step bioassay directly in human 
serum enables rapid molecular results, critical for the early diagnosis of sepsis, by detecting individual Au-NPs binding to Au-NHA. b) A prototype 
DENIS reader developed for highly sensitive and multiplexed detection of biomarkers. The device uses a CMOS camera and a narrow-band LED 
source to record the transmitted images from a nanoplasmonic chip. c) SEM image of a Au-NHA area after a bioassay showing the bound NPs. 
Inset shows a single nanoparticle bound inside a nanohole. d) Plasmonic image of a Au-NHA area with bound nanoparticles. The binding of Au-NPs 
on Au-NHAs causes local transmission suppression through distortion of plasmonic excitations in the Au-NHA and can be digitally detected using 
far-field imaging. The inset shows a normalized intensity contrast induced by a single nanoparticle trapped in a nanohole. e) To enable microarray 
based biosensing, capture antibodies are immobilized on the Au-NHA sensor surface using noncontact ultralow volume robotic liquid dispenser. 
The image shows nine sensor chips with spotted microarrays under dispensing nozzle. f) Photograph of a Au-NHA plasmonic chip. The sensors 
are fabricated using wafer-scale DUVL lithography. g) Image of a plasmonic microarray field of view with antibody spots, and labeled with QR codes.
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3.45 µm pixel size. Each image shows a 900 µm × 700 µm field 
of view (FOV) with ≈1.2 µm resolution (Figure 1g). The reader 
weight is below 1 kg and the dimensions are 10 × 10 × 35 cm. 
Such compactness means it is easily transportable and can be 
deployed in most on-site settings.
The control of the camera, image acquisition, and data pro-
cessing are performed on a laptop computer using custom 
Matlab functions. In brief, images are recorded with custom auto-
exposure to ensure optimal intensity profile, corrected for source 
illumination, and the NPs binding is quantified over the sensing 
spots by computing the percentage of dark pixels using a cutoff 
threshold. QR tags from the images can be automatically recog-
nized by custom Matlab function to register individual FOVs. For 
end-point measurements, signals from at least five microarray 
areas from each sensor chip are recorder for statistical signifi-
cance. In the case of time-resolved measurements, images of a 
single FOV are recorded with 30 s intervals, and the signals are 
extracted from at least three microarray spots to estimate mean 
and standard deviation. In order to control for nonspecific NPs 
binding and background fluctuations, in each measurement the 
signals from bovine serum albumin (BSA) blocked background 
are subtracted from the signals of Ab microarray spots.
2.4. Bioassay
Our simple and rapid bioassay is performed in a single step, 
where antibody functionalized Au-NP (Ab-NP) suspension 
is mixed directly with blood serum and then injected into the 
measurement chamber (Figure 2). We pre-
pare large batches of Ab-NPs with optical 
density OD = 20 and store them in phos-
phate buffer saline (PBS 1×) buffer with BSA 
(1% w/v) and Tween20 (0.05 % w/v). The 
Ab-NP suspension is stable at 4 °C for at least 
5 weeks, over which the tests were performed. 
The sensor chips are first uniformly function-
alized with copoly-DMA-MAPS-NAS-fluori-
nated polymer (MCP-2F), containing activated 
amine reactive NHS-ester groups, to ensure 
stable antibody immobilization. Moreover, 
the fluorocarbon polymer helps prevent non-
specific NP binding, and fouling by serum 
proteins.[34] To form antibody microarrays, 
we spot antibodies specific to the biomarkers 
as well as mouse isotype immunoglobulin-G 
(IgG) for nonspecific negative control both at 
200 µg mL−1. Each microarray spot of ≈150 µm 
diameter is formed by a single 400 pL droplet 
dispensed with 400 µm period. Importantly, 
the use of microarray printer not only enables 
functionalization of large number of chips, 
but also minimizes the amount of antibodies 
used, which are one of the most expensive 
components of the assay. The uniform anti-
body immobilization on the sensor surface is 
ensured by adding trehalose (0.5% w/v) and 
Tween20 (0.01% w/v) in the PBS 1× spotting 
buffer. The sensor chips with IgG microar-
rays are blocked with BSA (1% w/v) to minimize the nonspecific 
binding. A capillarity-based disposable microfluidic platform is 
sealed on the sensor chips using a silicone spacer.[33] The anti-
body immobilized chips can be stored at 4 °C stably for at least 
5 weeks (Figure S6, Supporting Information). To increase the per-
formance of our assay, we optimized a stabilizing buffer, which 
consists of PBS Tween20 (PBST, 1×, 0.05% w/v) and NaOH 
(50 × 10−3 m) in 3:1 ratio. To perform the bioassay, 20 µL of 
serum is mixed with 4 µL of Ab-NP suspension and 16 µL of sta-
bilizing buffer, and the mixture is loaded into the measurement 
chamber with a pipet. The loaded cartridge is either inserted 
into the reader for time-resolved data acquisition or measured 
after an incubation period.
To characterize the performance of DENIS system, calibra-
tion titration curves were obtained by spiking known amounts 
of PCT and CRP biomarkers in reference samples (Figure 3). 
Each data point represents mean value and standard deviation 
from five measurements collected from different microarray 
areas. The LOD values were estimated by measuring the mean 
signal from blank samples and adding three times the standard 
deviation. Our detection method achieves LOD of 21 and 
36 pg mL−1 for PCT and CRP, respectively. Moreover, the PCT 
detection dynamic range of DENIS is three orders of magni-
tude (i.e., from ≈21 to >1E4 pg mL−1). The clinical serum levels 
of PCT usually range from tens of pg mL−1 for healthy individ-
uals to few hundreds pg mL−1 for SIRS patients free of bacterial 
infection, and above ≈1 ng mL−1 in sepsis patients.[35] Therefore, 
our method covers the full relevant diagnostic range. The clin-
ical serum levels for CRP range from few µg mL−1 for healthy 
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Figure 2. Detection and quantification of PCT and CRP using DENIS. A serum sample (I) is 
mixed with Au-NPs functionalized with antibodies against PCT or CRP. Ab-NPs bind to the 
antigen in serum (II). Sample with Ab-NPs is injected on Au-NHA sensor chip functionalized 
with polymer and spots of complementary aPCT or aCRP antibodies as well as nonspecific 
mouse IgG as negative control. Ab-NPs bind on the Au-NHA chip functionalized with comple-
mentary antibody spots in a sandwich assay in the presence of the antigen (III).
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individuals to hundreds of µg mL−1 for septic patients,[35] which 
are significantly higher than the values for PCT. To measure 
them with the same assay, we diluted serum for CRP measure-
ments in order to comply with the dynamic range of the device, 
which covers from 36 to 1E5 pg mL−1. Importantly, the sensi-
tivity and dynamic range enabled by DENIS are similar to the 
performance of gold standard lab techniques, without the need 
for time-consuming amplification and washing steps or bulky 
readout equipment.
2.5. Clinical Tests of the DENIS System
We deployed the DENIS system at the Vall d’Hebron University 
Hospital and tested with clinical samples previously collected 
from patients with sepsis, noninfectious SIRS and healthy 
individuals (previous informed consent agreement). Even 
though the new sepsis definitions prefer to avoid the term 
SIRS, this clinical condition is still worthy when defining 
the appropriate study groups with research purposes.[1] We 
obtained and measured on the DENIS platform samples, previ-
ously anonymized, from 34 individuals, including 18 patients 
with sepsis, 11 with noninfectious SIRS, and 5 healthy donors 
(Table S1, Supporting Information). The detection of PCT and 
CRP levels in the patient serum was performed as described 
above using only 20 µL of sample for each measurement. 
The measurements were done in a blind manner, where nei-
ther the patient status nor the biomarker concentrations were 
disclosed during the testing in order to eliminate bias. After 
the completion of the clinical tests, the results collected from 
DENIS assay were compared with the routine clinical determi-
nations. Specifically, CRP and PCT detection were performed 
using ITA and CLIA, respectively, and bacterial infection was 
determined with blood culture. The example images of single 
PCT spots obtained by DENIS system directly in serum from 
the three patient groups are presented in Figure 4a. Samples 
from septic patients contain high levels of PCT or CRP, and 
result in dense binding of particles on antibody microspots of 
the Au-NHA sensor, while noninfectious SIRS samples pro-
duce images with sparsely bound NPs, and healthy samples 
present negligible NP binding on the sensing areas. Figure 4b 
shows CRP and PCT values measured from nine representa-
tive individuals from the three groups. Each data point repre-
sents the mean and STD from at least five different spots. We 
observed consistent results correlating the PCT readouts from 
DENIS to the CLIA measurements in the clinical lab (inset 
Figure 4b). In every sample measured, we controlled for non-
specific interactions between Ab-NPs and the Au-NHA surface 
by recording signals from mouse IgG spots and BSA blocked 
areas (Figure 5). Notably, we observed no significant signals 
from these control measurements on every chip tested, there-
fore no washing steps were needed.
To validate the performance of the DENIS platform, we 
mapped the PCT and CRP detection results of 34 individuals 
to the measurements with CLIA and ITA, based on the clinical 
diagnosis (see Figure 6a,b and Figure S3 in the Supporting 
Information). In the sampled group, the measured levels 
of PCT and CRP using both DENIS and clinical assays were 
significantly elevated in noninfectious SIRS group compared 
to healthy subjects (PPCT DENIS < 1.7E−5, PCRP DENIS < 1.7E−3, 
unpaired t-test), and in sepsis group compared to noninfectious 
SIRS (PPCT DENIS < 2.3E−7, PCRP DENIS < 4.9E−3, unpaired t-test). 
However, CRP was reported in multiple sources to be a gen-
eral inflammatory marker that is not well discriminative of the 
stage or the source of inflammatory host response.[35,36] There-
fore, in order to compare the performance of DENIS to clini-
cally validated assays in assisting the discrimination between 
sepsis, noninfectious SIRS, and healthy groups, we constructed 
receiver operating characteristic (ROC) curves using PCT meas-
urements with both techniques as a predictor (Figure 6c,d). 
We also calculated the corresponding area under the curve 
(AUC). ROC curves are an established metric to analyze 
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Figure 3. Determining the detection sensitivity for PCT and CRP bio-
markers with the DENIS system. The calibration curves were obtained by 
titrating a known concentration of a) PCT or b) CRP and measuring the 
associated signal.
Figure 4. a) Different concentration of PCT in serum results in different 
density of particle binding. From left to right: representative microspots 
imaged from clinical samples associated to a sepsis patient, a noninfec-
tious SIRS patient, and a healthy donor are shown. b) Quantification of 
PCT and CRP biomarkers using DENIS in the serum of typical representa-
tive patients with sepsis, noninfectious SIRS and healthy controls. Error 
bars represent standard deviation between signals of five spots measured 
for each sample. Inset shows correlation between DENIS and CLIA meas-
urements of PCT levels for the typical patients.
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diagnostic ability of a test to discriminate the true state of sub-
jects, and to compare two alternative diagnostic tests when each 
is performed on the same subject.[37] DENIS measurements 
of PCT provided equivalent performance to CLIA in discrimi-
nating between the three study groups. With both methods, 
we observed 100% sensitivity and specificity in classifying 
between healthy and sick subjects, moreover PCT was a good 
indicator of host response in sepsis compared to noninfectious 
SIRS, with AUC = 0.995, sensitivity = 0.944, and specificity = 1. 
Although the patient cohort of 34 subjects is not large enough 
to reflect the general population statistics, these findings are in 
agreement with the literature, where PCT levels in blood were 
shown to be a useful indicator to assist in discrimination of 
noninfectious SIRS from sepsis patients.[35,36] Importantly, the 
results of the DENIS assay showed robust performance, even 
though the patients serum samples presented significant visual 
differences in the color and consistency (Figure S4, Supporting 
Information).
2.6. Rapid Biomarker Detection
Rapid turnaround time is an essential characteristic of a sepsis 
diagnostic device, as sepsis is a time-dependent emergency 
with a severe disease progression within hours. We show the 
diagnostic use of DENIS with minimal time-to-result enabled 
by time-resolved measurements. The system can record real-
time video of the sensor (Video S5, Supporting Information), 
from which NP binding signals are extracted and analyzed in 
real time. In Figure 7, we present time-resolved PCT detec-
tion signals from sera of representative sepsis patients, non-
infectious SIRS patients, and healthy individuals. Each plot 
shows mean signal from three PCT sensing spots and its 95% 
confidence interval in the shaded area. To establish the back-
ground signal and its variation, we plot averaged signal from 
three BSA blocked areas and compute the running time aver-
aged 95% confidence interval. We consider a reliable detection 
when the PCT signal’s 95% lower confidence interval exceeds 
the background’s upper confidence interval. We characterized 
PCT cutoff detection times for high (sepsis), medium (non-
infectious SIRS) and low (healthy) PCT concentration groups 
and observed that we detect sepsis levels in less than 5 min and 
noninfectious SIRS levels in around 10 min, while PCT signal 
from healthy individuals did not significantly exceed back-
ground over 2 h. These results show that PCT detection can be 
performed in under 15 min, including sample mixing, injec-
tion and readout, which is particularly important in intensive 
care units.
1906108 (6 of 11) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimSmall 2020, 16, 1906108
Figure 5. Quantification of plasmonic imaging signals for a) PCT and b) CRP, as well as from nonspecific mouse isotype control antibody spots, for 
every patient. The two biomarkers were measured for 34 subjects, including 18 sepsis patients, 11 noninfectious SIRS patients, and 5 healthy controls. 
The signal from mouse antibodies was small for all patients, indicating little nonspecific interactions between Ab-NPs and Au-NHA sensor. Signals 
plotted as difference between signal from Ab spots and BSA background. For each point, at least five different antibody spots were measured to estimate 
the mean and the standard deviation of the signal.
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3. Discussion
DENIS device proved to be particularly suitable for on-site 
operation due to its portability, inexpensive off-the-shelf optical 
components, and because it does not involve any moving parts 
or complex microfluidic elements prone to clogging. Impor-
tantly, the sensor chips and bioassay reagents can be stored 
in the fridge stably over weeks and unlike previously reported 
optical detection schemes[21–23] do not require fluorescent tags 
that can be expensive, unstable, and difficult to produce. The 
simple and rapid bioassay enables highly sensitive and robust 
detection of PCT and CRP, covering the full clinically relevant 
ranges. The high sensitivity of the assay is enabled by the 
unique plasmonic mechanism that works by detecting indi-
vidual molecules on the Au-NHA surface through imaging of 
single Au-NPs, without the need for complex signal amplifica-
tion procedures. The system achieved 21.3 pg mL−1 LOD sen-
sitivity for PCT and 36 pg mL−1 LOD for CRP, and a dynamic 
range of at least three orders of magnitude, which is well within 
the clinical biomarker levels.
DENIS was validated with measurements of PCT and CRP 
biomarkers from sera of 34 individuals, including 18 sepsis 
patients, 11 noninfectious SIRS patients, and 5 healthy controls, 
and was shown to provide consistent and robust performance 
at the level of gold-standard immunoassays. Both PCT and CRP 
levels were significantly elevated in the sick groups compared 
to healthy subjects. In the sampled group DENIS measure-
ments of PCT levels showed performance equivalent to clini-
cally validated assay in assisting classification between sepsis 
and noninfectious SIRS patients, with 94.4% sensitivity and 
100% specificity. These results show that DENIS platform can 
be effectively deployed to help rapidly triage patients between 
noninfectious SIRS and sepsis groups. The detection is robust 
against background noise, nonspecific adsorption of proteins, 
and variations in optical properties of the serum, enabling 
reliable detection. In combination with small sample volume 
used (20 µL), this makes DENIS suitable for frequent bio-
marker testing, such as required during treatment response 
monitoring.
The sensor chips were fabricated in a robust wafer-scale cost-
effective process using DUVL lithography. The functionaliza-
tion of sensors was performed in a scalable way with microarray 
bioprinter that uses minimal amounts of antibodies. In combi-
nation with easy-to-use bioassay and a compact optical reader, 
this makes the DENIS technology suitable for the development 
of a clinical diagnostic device. Owing to the high sensitivity, 
rapid time to result, compactness and cost efficiency, DENIS is 
expected to be employed in hospitals as well as small clinic and 
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Figure 6. PCT measurements using DENIS to assist diagnosis. Samples from 34 clinically diagnosed individuals, including 18 sepsis patients, 11 
noninfectious SIRS patients, and 5 healthy controls, were tested. Box and whiskers plot with scattered data points for sepsis, noninfectious SIRS and 
healthy samples are shown for a) plasmonic DENIS and b) clinical CLIA measurements. Each data point represents an individual patient. PCT serum 
levels were significantly higher for noninfectious SIRS group compared to healthy (P < 1.7e−5 and P < 1.1e−5 with DENIS and CLIA, respectively), and 
for sepsis compared to noninfectious SIRS group (P < 2.3e−7 and P < 1.1e−7 with DENIS and CLIA, respectively). Receiver−operation characteristic 
curves were constructed for PCT measurements with c) DENIS and d) CLIA. The performance of DENIS was equivalent to CLIA. For both methods, 
AUC is 1 to discriminate healthy from sick patients. PCT levels also provided good classification between noninfectious SIRS and sepsis patients, with 
AUC = 0.995, sensitivity = 0.944, and specificity = 1 for both methods.
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physician’s office settings, where the access to large and costly 
laboratory testing equipment is limited, therefore assisting 
timely diagnosis and reducing antibiotic prescription.
We envision several ways in which the current DENIS system 
could be improved. First, the imaging readout enables scaling 
up the test for multiplexed measurements.[38] Sepsis manifests 
in a complex system of pathophysiological responses, spanning 
multiple organs. Creating a sepsis marker panel and expanding 
DENIS to multiplexed detection of relevant biomarkers with 
comparable dynamic ranges, such as presepsin, MR-pro-adre-
nomedullin, pancreatic stone protein, and interleukin 6 from 
no more than few µL of sample could provide more robust 
characterization of the patient’s host response and potentially 
predict survival.[13,25,39,40] Importantly, the detection principle is 
not limited to proteins and can be extended to small peptides, 
DNA, or RNA, as long as a pair of complementary recogni-
tion elements is available. The development of the bioassay 
to operate with whole blood would deliver even faster time to 
result by eliminating serum extraction step and better posi-
tion the test for the use in resource-limited settings. Further 
reducing the costs of the imager and scaling up the production 
of Au-NHA sensors would push the per-test costs even lower 
and open the path to potential market entry. Finally, the devel-
opment of a fully integrated easy-to-use software interface will 
facilitate introduction of the device to clinical professionals and 
help validate the technology on large sets of clinical samples.
4. Conclusion
Our study reports a portable digital nanoparticle-enhanced plas-
monic imager that enables rapid detection of two inflammatory 
sepsis-related biomarkers, PCT and CRP. The unique nanoplas-
monic mechanism through imaging of single Au-NPs binding 
on the Au-NHAs enables highly sensitive and rapid biomarker 
detection directly in blood serum. The compact nanoplasmonic 
reader, built of inexpensive components, weighs less than 1 kg. 
The portable device was deployed in hospital settings, where it 
was shown to provide equivalent performance to gold-standard 
laboratory assays using a wide range of samples from patients 
with sepsis, noninfectious SIRS, and healthy donors. Moreover, 
identification of PCT levels typical for sepsis, SIRS, and healthy 
subjects can be performed in less than 15 min, which is signifi-
cantly faster than laboratory immunoassays. Therefore, DENIS 
platform promises to become a powerful tool in managing 
acute inflammatory conditions at the point-of-care in an afford-
able way, improving the quality of health care for more people.
5. Experimental Section
Au-NHA Sensor Fabrication: Au-NHAs were produced using wafer-
scale low-cost DUVL process and ion beam etching. Fused silica wafers 
with 4 in. diameter were used as substrate. The wafers were cleaned 
with RCA solution (1:1:5 H2O2:NH4OH:H2O by volume) for 15 min, 
rinsed with deionized water for 5 min, and dried under nitrogen stream. 
Next, the cleaned wafers were coated with 10 nm of titanium (Ti) and 
120 nm of gold (Au) using Alliance-Concept EVA 760 electron-gun 
evaporator. The NHAs with 200 nm diameter and 600 nm period were 
patterned over whole wafers using a 248 nm deep-UV stepper (ASML 
PAS 5500/300 DUV). The exposed wafers were treated with ion-beam 
etching (Oxford Instruments PlasmaLab 300 IBE), to transfer the 
nanohole arrays into metal films. The photoresist was stripped using 
oxygen plasma.
To label the Au-NHA sensors, QR codes were formed with 50 nm 
Ti film. The NHA wafers were coated with 1.3 µm thick lift-off positive 
photoresist (AZ1512) using Süss ACS200 Gen3 coater, and the QR 
microarray patterns were exposed using Heidelberg Instruments 
MLA150 Maskless Aligner. The resist was developed, and 50 nm Ti 
film was evaporated using an electron gun evaporator. Wafers covered 
with photoresists and Ti were diced into 1 × 1 cm2 sensor chips, 
and the photoresist was removed from chips by immersing in resist 
remover with sonication at 70 °C overnight. The final chip cleaning was 
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Figure 7. Time-resolved PCT detection using DENIS. Real-time measure-
ments of selected subjects: a) high PCT content (sepsis patient, [PCT] = 
24.26 ng mL−1), b) medium PCT content (noninfectious SIRS patient, 
[PCT] = 0.79 ng mL−1), and c) low PCT content (healthy control subject, 
[PCT] < 50 pg mL−1). Error bars from the PCT signal represent 95% con-
fidence interval extracted from data collected from three different aPCT 
antibody microspots from a single image frame. The background signals 
are collected from three off-the spot BSA blocked areas. The blue shaded 
intervals indicate dynamic time averaged 95% confidence interval for 
background signal. Insets show the first 30 min time period. The detec-
tion time is defined as the cutoff point when the PCT signal’s 95% lower 
confidence interval exceeds the background’s upper confidence interval. 
The detection time is estimated to be less than 5 min for sepsis and 
10 min for noninfectious SIRS.
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performed with oxygen plasma for 5 min at 500 W and 1 min immersion 
in RCA solution (1:1:5 H2O2:NH4OH:H2O) to ensure uniformly clean Au 
surface.
Chemicals and Biologicals: Ammonium hydroxide solution (ACS 
reagent, 28–30%), hydrogen peroxide (H2O2 30%), BSA lyophilized, PBS, 
Tween20, and d-(+)-trehalose dihydrate were purchased from Sigma-
Aldrich. MCP-2F polymer was bought from Lucidant. Ethanol (EtOH) 
absolute was from Thermo Chemicals. Pierce protease inhibitor (PI) 
tablets, recombinant human PCT and anti-PCT monoclonal antibodies 
QNO5 and CALC, used for spotting on Au-NHA and NP conjugation, 
respectively, were provided by ThermoFisher (BRAHMS). Antihuman 
C-reactive protein monoclonal IgG antibodies PCR-196 and PCR-183, 
used as capture and recognition antibodies, respectively, were provided 
by Diesse Diagnostica Senese. Au-NP conjugation kit with lyophilized 
spherical Au-NPs of 100 nm dimeter coated with polyethylene glycol 
(PEG, 10 kDa) and activated with 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide-N-hydroxysuccinimide chemistry (EDC-NHS), were 
purchased from Cytodiagnostics.
Au-NHA Functionalization: Au-NHA chips were coated with MCP-2F 
(copoly-DMA-MAPS-NAS-fluorinated) polymer (Lucidant) to yield 
stable and reproducible functionalization with Ab microarray spots 
and prevent the sensors from nonspecific fouling by serum and NPs. 
The polymer contains activated NHS-ester groups that enable covalent 
immobilization of molecules through amino groups. The MCP-2F 
polymer stock was diluted with coating solution from Lucidant, and 
the Au-NHA chips were immersed in the solution for 30 min at room 
temperature. Next, the Au-NHA sensors were washed in large volumes 
of mQ water and dried under nitrogen stream. The sensors were placed 
in a vacuum oven at 80 °C for 15 min (<2 mmHg) to dry the polymer 
and ensure stable adhesion to the Au surface. Polymer-functionalized 
chips were immediately spotted with Ab microarrays because NHS-ester 
groups of the polymer degrade in the presence of air humidity.
The Ab microarrays were formed on the sensors by spotting Ab 
solutions on polymer coated Au-NHA surface using noncontact 
piezoelectric ultralow volume dispensing system (sciFLEXARRAYER S3, 
Scienion). Spotting solutions containing Ab specific against PCT, or 
CRP, or mouse isotype control IgG, all at 200 µg mL−1 were prepared 
in PBS 1× with trehalose (0.5% w/v) and Tween20 (0.01% w/v), 
to ensure uniform Ab distribution over each spot and stabilize Abs 
during sensor storage. Microarray spots of 400 pl were dispensed with 
a period of 400 µm inside a humid chamber. The humidity control 
was set at dew point (65% relative humidity) to prevent evaporation. 
The sensor chips with IgG microarrays were blocked with BSA 
(1% w/v) to inactivate nonreacted EDC-NHS groups and minimize the 
nonspecific binding. The sensor chips were stored until use at 4 °C for 
up to 4 weeks.
Au-NP Functionalization: Au-NPs of 100 nm diameter coated with 
10 kDa PEG and activated with EDC-NHS were functionalized with aPCT 
or aCRP antibodies according to the following protocol. Antibodies 
were diluted in protein resuspension buffer (Cytodiagnostics) to 
500 µg mL−1 concentration. The antibody solution (40 µL) was mixed 
with reaction buffer (50 µL, Cytodiagnostics), and added to the vial of 
lyophilized Au-NPs. The Au-NP mixture with Abs was incubated at room 
temperature for 4 h with a mild mixing using Eppendorf ThermoMixer at 
700 rpm. After incubation, 10 µL of quencher solution (Cytodiagnostics) 
was added to stop the reaction. The Au-NPs suspension was centrifuged 
at 150 rcf for 30 min to wash the NPs from nonreacted Abs. The 
supernatant was removed and NPs were resuspended in 1 mL of PBS 
1× with 1% w/v BSA and 0.05% w/v Tween20. Centrifugation and 
resuspension steps were repeated 3 times. At the final resuspension 
step, Au-NPs pellet was diluted in a 100 µL of PBS 1× with 1% w/v BSA 
and 0.05% w/v Tween20 to obtain Au-NP stock solution with optical 
density OD = 20 (measured at 572 nm), or 7.7E+10 NP mL−1. The 
Ab-NPs solution was stored at 4 °C for up to 4 weeks. Before performing 
bioassay, Ab-NPs were vortexed at 800 rpm for 30 s to resuspend the 
NPs.
Biobank Samples: Samples and data from the patients used in this 
study were provided by the Sepsis Bank of Vall d’Hebron University 
Hospital Biobank (PT17/0015/0047), integrated in the Spanish National 
Biobanks Network. Samples were processed following standard operating 
procedures with the appropriate approval of the Clinical Research Ethics 
Committee (approval reference number PR(AG)11/2016). Sample 
selection was done to ensure a wide range of concentrations to be 
measured with DENIS, from low PCT and CRP values associated with 
healthy individuals, to medium levels usually observed in noninfectious 
SIRS patients and increasing values that are characteristic of sepsis 
and septic shock patients. It should be noted that sepsis is a complex 
syndrome and patient groups could have overlapping biomarker levels. 
For each patient the samples were collected at a single time point. 
For sepsis patients, samples were collected at the time sepsis was 
diagnosed. For noninfectious SIRS patients, samples were collected 
in the immediate postoperative period. The samples were stored in 
500 µL aliquots at −80 °C in cryovials. Samples were handled on ice and 
protected from light.
Serum Bioassays: The bioassays were performed by mixing patient 
serum with the Ab-NP conjugates (aPCT or aCRP) and a stabilizing 
buffer and injecting the mixture into the sensor measurement chamber. 
A 20 µL aliquot of serum sample was mixed with 16 µL of buffer and 
4 µL of aPCT Ab-NP stock by gentle pipetting and inserted onto the 
measurement chamber. In the case of CRP measurements, the patient 
serum was first diluted in PBS 1× with bovine serum albumin 7%. 
The serum dilution was done in two steps, first 100 times and then 
500 times, to minimize the error, reaching the final dilution of 50 000 times. 
Then, a 20 µL aliquot of the diluted serum was mixed with 16 µL of 
measurement buffer and 4 µL of anti-CRP Ab-NPs by gentle pipetting 
and inserted to the sensor chamber. Sensor chamber was formed by 
placing a capillarity-based disposable microfluidic cartridge (Microtec) on 
the Au-NHA sensor chip using a silicone spacer for sealing. The loaded 
sensor was either immediately inserted into the portable reader for real-
time measurements or incubated at room temperature, and end-point 
readouts were taken at the end of the incubation period (2 h).
The stabilizing buffer was optimized to ensure optimal bioassay 
performance and prevent NP aggregation during the measurements. 
The buffer consists of 0.05% PBST 1× and 50 × 10−3 NaOH mixed in 
3:1 volume ratio.
Calibration Measurements: In order to perform calibration 
measurements of the PCT bioassay, known concentrations of 
recombinant human PCT (50 pg mL−1, 100 pg mL−1, 300 pg mL−1, 
500 pg mL−1, 1 ng mL−1, 3 ng mL−1, 10 ng mL−1, and 50 ng mL−1) were 
spiked in 7% BSA PBS 1× with protease inhibitors (1 tablet per 50 mL of 
buffer). Next, the calibration samples, as well as a blank negative control 
containing BSA 7% in PBS 1× and PI without PCT, were measured 
identically to the serum bioassays. A 20 µL aliquot of calibration sample 
was mixed with 16 µL of measurement buffer and 4 µL of Ab-NP, 
incubated over 2 h and measured with the portable reader to obtain the 
corresponding signals. For each calibration sample, at least five different 
antibody sensing spots were measured to compute the mean and the 
standard deviation of the signal.
To obtain calibration curve for CRP, serial dilutions of a real human 
sample were used with a known CRP concentration characterized by an 
immunoturbidimetric test (266.9 µg mL−1). The sample was diluted in 
BSA 7% PBS 1× at dilution ratios of 1:750 × 103, 1:500 × 103, 1:100 × 103, 
1:50 × 103, 1:10 × 103, and 1:103 times, and the measurements were 
performed identically to PCT. Calibration curves for PCT and CRP were 













where a is a theoretical response at zero concentration, b is a slope 
factor, c is a concentration inflection point, and d is a theoretical 
response at saturation.
Optical Reader: The nanoplasmonic imager is made of off-the-shelf 
optical components and effectively comprises a portable bright-field 
imaging microscope. A narrowband light emitting diode (LED) source 
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(Thorlabs M660L4 ) in combination with a bandpass filter with 660 nm 
center wavelength and 10 nm full width at-half-maximum (Thorlabs) is 
used for narrow-band illumination at the wavelength of Au-NHA EOT 
peak. The light from the LED is collimated with an aspherical condenser 
lens (Thorlabs). A custom aluminium holder for the sensor chamber 
was fabricated to accommodate the sensor inside the reader. The light is 
transmitted through the sample chamber, modulated by Au-NHA sensor, 
and the imaging is performed using a 50× objective (Nikon) and a black-
and-white CMOS camera (IDS B-UI-3200SE-M-GL). The CMOS camera 
has 4104 × 3006 pixels with 3.45 µm pixel size. The system enables 
imaging of ≈900 µm × 700 µm FOV area with an ≈1.5 µm resolution 
(diffraction-limited spot). The reader dimensions are 10 × 10 × 35 cm 
and the weight is less than 1 kg.
Image Processing: Image acquisition and processing was performed 
using custom Matlab functions and a graphical user interface from a 
laptop connected to the CMOS camera. Images from Au-NHA sensors 
were recorder using custom autoexposure function to ensure similar 
intensity profiles across all images, and so that image histogram is 
always covered by the dynamic range of the CMOS. The images were 
normalized by the background illumination to exclude the source 
variations. To extract the NP signal, image areas were analyzed using a 
fixed intensity threshold to quantify bound NPs. The percentage number 
of pixels in an area darker than the threshold was used for quantification. 
The intensity threshold was optimized by matching plasmonic images to 
scanning electron micrographs of identical Au-NHA areas to maximize 
the number of detected NPs, while minimizing false-positive signals.[27] 
Importantly, Au-NP aggregates can be identified and filtered out from 
the signal, as described previously.[27] A custom Matlab function was 
used to recognize QR codes from the images and extract encoded 
information. For the end-point measurements at least five different 
FOV were acquired and analyzed from each sensor chip for statistical 
significance. In order to control for nonspecific NPs binding and 
background fluctuations, signal from each measured spot was corrected 
by subtracting the signal from adjacent BSA blocked background area. 
During time-resolved measurements, the images of a single FOV were 
recorded with 30 s interval. Each field of view had at least three antibody 
spots, which enabled to assess the mean and standard deviation of the 
signal from each frame. In order to evaluate detection cutoff times, signal 
from three PCT sensing spots and its 95% confidence interval (±1.96*δ) 
were estimated at each time point. To establish the background signal 
and its variation, average from three BSA blocked areas is plotted at 
each time point and running time averaged at 95% confidence interval 
is computed. The time-averaged standard deviation at every time point 
T was computed to incorporate variances of background signals of all 









A reliable detection was considered when the PCT signal’s 95% lower 
confidence interval exceeds the background’s upper confidence interval.
Software Availability: All custom plug-ins associated with this 
manuscript are available upon request.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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